Friday 12/12 Insider Buying Report: ANVS, ECL

SEC filings show Annovis Bio director Michael B. Hoffman bought 45,000 shares of ANVS on Monday at $4.31 each ($193,794); the stock traded as low as $3.70 (14.1% below his purchase) and was up about 6.9% on Friday—Hoffman has previously bought into ANVS four times over the past year, totaling $2.26 million at an average price of $2.15. Also on Monday, David Maclennan purchased 750 shares of Ecolab (ECL) at $257.60 ($193,198); Ecolab was up roughly 0.5% on the day and briefly traded to $264.01 (about 2.5% above his buy), and Maclennan’s prior purchases this year total $398,786 at an average of $265.86. These filings indicate continued insider accumulation in both names, though market reaction is mixed with ANVS trading below the director’s latest buy and ECL modestly outperforming it intraday.

Analysis

SEC filings show Annovis Bio director Michael B. Hoffman purchased 45,000 ANVS shares on Monday at $4.31 each for $193,794; ANVS traded as low as $3.70 (14.1% below his purchase) and was up ~6.9% on Friday. Hoffman has accumulated ANVS four prior times over the last year totaling $2.26m at an average $2.15 per share, indicating meaningful, repeated insider accumulation. David Maclennan bought 750 Ecolab (ECL) shares at $257.60 ($193,198); ECL was up ~0.5% on Friday and traded as high as $264.01, and Maclennan’s prior ECL purchases total $398,786 at an average $265.86 with the intraday high putting him roughly in positive territory per the report.

Insider buying in both names carries a mildly positive market signal (sentiment score ~0.25) but presents different tactical implications: ANVS shows larger relative insider exposure and greater intraday price divergence versus Hoffman's buy, implying elevated volatility or near-term uncertainty; ECL purchases sit near recent trading levels and suggest steady, lower-volatility conviction. Investors should treat ANVS insider activity as a signal to monitor for confirming catalysts or further buys before scaling, while ECL insider activity supports a more conservative hold or modest add thesis, with attention to short-term price resistance and subsequent filings.

Key Decisions for Investors

• For ANVS: consider monitoring for follow-on insider purchases or specific clinical/corporate catalysts before initiating a full-sized position and, if adding, size positions conservatively given the stock traded 14.1% below the director's buy and has shown intraday volatility
• For ECL: consider modest accumulation or holding existing exposure because insider buying is consistent and the purchase price ($257.60) sits near recent trading; monitor whether shares can sustain moves above the ~$264 intraday level and the insider's prior average of $265.86
• Across both names: track subsequent SEC insider filings and trading volume as confirmation signals and use disciplined position sizing or hedges to limit downside while waiting for confirming price action